by
Thomas Dworetzky, Contributing Reporter | June 12, 2018
Also in October, 2017, Boston Scientific
agreed to acquire Apama Medical for $300 million.
The acquisition of the privately-held, California-based company will allow Boston Scientific to expand its electrophysiology portfolio, combining its radiofrequency point-by-point solution with Apama’s single-shot balloon ablation technology for the treatment of atrial fibrillation (AF).
Ad Statistics
Times Displayed: 131193
Times Visited: 7455 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
“Single-shot pulmonary vein isolation (PVI) ablation is a high-growth market segment,” Joe Fitzgerald, president of rhythm management at Boston Scientific, told HCB News. “Our current electrophysiology (EP) portfolio includes a radiofrequency (RF) point-by-point solution, and the Apama technology, upon regulatory approval, will allow us to expand into the single-shot market segment, and ultimately bolster our entire EP portfolio.”
Back to HCB News
